Latest news with #BioSyent
Yahoo
19-05-2025
- Business
- Yahoo
BioSyent (CVE:RX) Has Announced A Dividend Of CA$0.05
The board of BioSyent Inc. (CVE:RX) has announced that it will pay a dividend on the 13th of June, with investors receiving CA$0.05 per share. This payment means the dividend yield will be 1.7%, which is below the average for the industry. We've discovered 1 warning sign about BioSyent. View them for free. Even a low dividend yield can be attractive if it is sustained for years on end. Before making this announcement, BioSyent was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business. Over the next year, EPS is forecast to expand by 10.4%. If the dividend continues along recent trends, we estimate the payout ratio will be 25%, which is in the range that makes us comfortable with the sustainability of the dividend. View our latest analysis for BioSyent Looking back, the dividend has been stable, but the company hasn't been paying a dividend for very long so we can't be confident that the dividend will remain stable through all economic environments. The annual payment during the last 2 years was CA$0.16 in 2023, and the most recent fiscal year payment was CA$0.20. This means that it has been growing its distributions at 12% per annum over that time. The dividend has been growing rapidly, however with such a short payment history we can't know for sure if payment can continue to grow over the long term, so caution may be warranted. The company's investors will be pleased to have been receiving dividend income for some time. We are encouraged to see that BioSyent has grown earnings per share at 14% per year over the past five years. BioSyent definitely has the potential to grow its dividend in the future with earnings on an uptrend and a low payout ratio. Overall, we like to see the dividend staying consistent, and we think BioSyent might even raise payments in the future. The company is easily earning enough to cover its dividend payments and it is great to see that these earnings are being translated into cash flow. All of these factors considered, we think this has solid potential as a dividend stock. Market movements attest to how highly valued a consistent dividend policy is compared to one which is more unpredictable. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. For example, we've picked out 1 warning sign for BioSyent that investors should know about before committing capital to this stock. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
15-05-2025
- Business
- Yahoo
BioSyent Releases Financial Results for First Quarter 2025
MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. ('BioSyent', TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2025. Key highlights include: (CAD) Q1 2025 % Change vs. Q1 2024 Trailing Twelve Months (TTM) Mar 31, 2025 % Change vs. TTM Mar 31, 2024 Canadian Pharma Sales 9,159,652 +21 % 34,544,657 +13 % International Pharma Sales 1,535,216 n/a 2,465,191 +135 % Legacy Business Sales 284,092 +52 % 1,266,373 +15 % Total Company Sales 10,978,960 +42 % 38,276,221 +17 % EBITDA1 3,201,647 +45 % 10,340,466 +20 % Net Income After Taxes (NIAT) 2,319,933 +31 % 7,821,310 +11 % Fully Diluted EPS 0.20 +35 % 0.67 +14 % Return on Average Equity for TTM March 31, 2025 was 22% as compared to 21% for TTM March 31, 2024 During Q1 2025, repurchased for cancellation a total of 19,500 common shares under Normal Course Issuer Bid (NCIB) Paid quarterly cash dividend of $0.05 per common share on March 14, 2025 Declared subsequent cash dividend of $0.05 per common share to be paid on June 13, 2025 Delivered first shipments of Tibelia® (tibolone) during Q1 2025 following acquisition of global product rights in September 2024 '2025 got off to a strong start with growth from each of our Canadian Pharma, International Pharma and Legacy businesses,' commented Mr. René Goehrum, President and CEO of BioSyent. 'FeraMAX® Pd sales, which included strong growth from the FeraMAX® Pd Maintenance 45 product (launched in 2023), grew by 18% over the comparative quarter. FeraMAX® Pd's position as Canada's leader in iron health was further bolstered by its recognition in April 2025 as the #1 recommended OTC oral iron supplement by Canadian physicians and pharmacists in an independent national survey for the tenth consecutive year. We continue to build on this leadership position by further developing and expanding the FeraMAX® Pd line of products.' 'Our Tibella® (tibolone) product also continued its sales momentum in Canada during the first quarter with 53% growth over the comparative period. Each Tibella® sale in Canada is now more profitable to BioSyent with improved gross margins following our September 2024 acquisition of the worldwide rights to Tibelia® (tibolone) and a direct source of supply. We also delivered our first international Tibelia® orders to several distributors around the world following the acquisition, generating new revenues of $0.8 million in the first quarter with further deliveries planned throughout the balance of 2025.' 'All of our businesses performed well during the first quarter in spite of the backdrop of uncertainty created by escalating tariffs, counter-measures and threats between international trading partners. The tariff situation is unpredictable and the resulting economic fallout continues to evolve. While there has been no direct impact to the performance of our business from the tariff situation to date, the broader impact of trade barriers on the Canadian economy and the Canadian consumer is uncertain. We continue to monitor this situation and to mitigate any potential risks to our customers, supply chains, and business operations. As always, we remain focused on patients and continuing to deliver on our strategic priorities of long-term, profitable growth and portfolio diversification.' 'In addition to these strong Q1 financial results, I am pleased to announce the election to the Board of Directors today of Mr. Prakash Gowd, who replaces Mr. Larry Andrews upon his retirement from the Board. Mr. Gowd is an accomplished business leader with extensive healthcare industry experience and expertise. He will be an asset to the Board through the next phase of BioSyent's continued growth. I would like to thank Mr. Andrews for his 7 years of service on the Board and his commitment and contributions to BioSyent's continued success during his tenure.' The CEO's presentation on the Q1 2025 Results is available at the following link: The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three months ended March 31, 2025 and 2024 will be posted on on May 15, 2025. For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol 'RX', BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units. As of the date of this press release, the Company has 11,254,638 common shares outstanding. BioSyent Inc. Interim Unaudited Condensed Consolidated Statements of Comprehensive Income In Canadian Dollars Q1 2025 Q1 2024 % Change Net Revenues 10,978,960 7,733,636 42 % Cost of Goods Sold 2,641,768 1,589,762 66 % Gross Profit 8,337,192 6,143,874 36 % Operating Expenses and Finance Income/Costs 5,180,821 3,737,443 39 % Net Income Before Tax 3,156,371 2,406,431 31 % Tax (including Deferred Tax) 836,438 637,704 31 % Net Income After Taxes 2,319,933 1,768,727 31 % Net Income After Taxes % to Net Revenues 21 % 23 % EBITDA1 3,201,647 2,204,193 45 % EBITDA1 % to Net Revenues 29 % 29 % EBITDA – is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization. BioSyent Inc. Interim Unaudited Condensed Consolidated Statements of Financial Position AS AT March 31, 2025 December 31, 2024 % Change ASSETS Cash, cash equivalents and short-term investments $ 17,401,557 $ 15,940,971 9 % Trade and other receivables 5,426,657 2,906,829 87 % Inventory 5,277,242 5,328,086 -1 % Prepaid expenses and deposits 484,654 201,971 140 % Derivative asset - 5,790 - Loans receivable - current 52,004 87,433 -41 % CURRENT ASSETS 28,642,114 24,471,080 17 % Long term investments 7,497,025 10,103,571 -26 % Loans receivable - non current 123,170 141,140 -13 % Deferred tax asset 380,206 401,166 -5 % Property and equipment 1,153,985 1,200,992 -4 % Intangible assets 4,965,682 5,041,501 -2 % NON CURRENT ASSETS 14,120,068 16,888,370 -16 % TOTAL ASSETS $ 42,762,182 $ 41,359,450 3 % LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES $ 5,846,653 $ 5,405,106 8 % NON CURRENT LIABILITIES 903,733 951,159 -5 % Long term debt - - 0 % Total Equity 36,011,796 35,003,185 3 % TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 42,762,182 $ 41,359,450 3 % For further information please contact: Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@ 905-206-0013Web: This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Yahoo
15-05-2025
- Business
- Yahoo
BioSyent Releases Financial Results for First Quarter 2025
MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. ('BioSyent', TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2025. Key highlights include: (CAD) Q1 2025 % Change vs. Q1 2024 Trailing Twelve Months (TTM) Mar 31, 2025 % Change vs. TTM Mar 31, 2024 Canadian Pharma Sales 9,159,652 +21 % 34,544,657 +13 % International Pharma Sales 1,535,216 n/a 2,465,191 +135 % Legacy Business Sales 284,092 +52 % 1,266,373 +15 % Total Company Sales 10,978,960 +42 % 38,276,221 +17 % EBITDA1 3,201,647 +45 % 10,340,466 +20 % Net Income After Taxes (NIAT) 2,319,933 +31 % 7,821,310 +11 % Fully Diluted EPS 0.20 +35 % 0.67 +14 % Return on Average Equity for TTM March 31, 2025 was 22% as compared to 21% for TTM March 31, 2024 During Q1 2025, repurchased for cancellation a total of 19,500 common shares under Normal Course Issuer Bid (NCIB) Paid quarterly cash dividend of $0.05 per common share on March 14, 2025 Declared subsequent cash dividend of $0.05 per common share to be paid on June 13, 2025 Delivered first shipments of Tibelia® (tibolone) during Q1 2025 following acquisition of global product rights in September 2024 '2025 got off to a strong start with growth from each of our Canadian Pharma, International Pharma and Legacy businesses,' commented Mr. René Goehrum, President and CEO of BioSyent. 'FeraMAX® Pd sales, which included strong growth from the FeraMAX® Pd Maintenance 45 product (launched in 2023), grew by 18% over the comparative quarter. FeraMAX® Pd's position as Canada's leader in iron health was further bolstered by its recognition in April 2025 as the #1 recommended OTC oral iron supplement by Canadian physicians and pharmacists in an independent national survey for the tenth consecutive year. We continue to build on this leadership position by further developing and expanding the FeraMAX® Pd line of products.' 'Our Tibella® (tibolone) product also continued its sales momentum in Canada during the first quarter with 53% growth over the comparative period. Each Tibella® sale in Canada is now more profitable to BioSyent with improved gross margins following our September 2024 acquisition of the worldwide rights to Tibelia® (tibolone) and a direct source of supply. We also delivered our first international Tibelia® orders to several distributors around the world following the acquisition, generating new revenues of $0.8 million in the first quarter with further deliveries planned throughout the balance of 2025.' 'All of our businesses performed well during the first quarter in spite of the backdrop of uncertainty created by escalating tariffs, counter-measures and threats between international trading partners. The tariff situation is unpredictable and the resulting economic fallout continues to evolve. While there has been no direct impact to the performance of our business from the tariff situation to date, the broader impact of trade barriers on the Canadian economy and the Canadian consumer is uncertain. We continue to monitor this situation and to mitigate any potential risks to our customers, supply chains, and business operations. As always, we remain focused on patients and continuing to deliver on our strategic priorities of long-term, profitable growth and portfolio diversification.' 'In addition to these strong Q1 financial results, I am pleased to announce the election to the Board of Directors today of Mr. Prakash Gowd, who replaces Mr. Larry Andrews upon his retirement from the Board. Mr. Gowd is an accomplished business leader with extensive healthcare industry experience and expertise. He will be an asset to the Board through the next phase of BioSyent's continued growth. I would like to thank Mr. Andrews for his 7 years of service on the Board and his commitment and contributions to BioSyent's continued success during his tenure.' The CEO's presentation on the Q1 2025 Results is available at the following link: The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three months ended March 31, 2025 and 2024 will be posted on on May 15, 2025. For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol 'RX', BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units. As of the date of this press release, the Company has 11,254,638 common shares outstanding. BioSyent Inc. Interim Unaudited Condensed Consolidated Statements of Comprehensive Income In Canadian Dollars Q1 2025 Q1 2024 % Change Net Revenues 10,978,960 7,733,636 42 % Cost of Goods Sold 2,641,768 1,589,762 66 % Gross Profit 8,337,192 6,143,874 36 % Operating Expenses and Finance Income/Costs 5,180,821 3,737,443 39 % Net Income Before Tax 3,156,371 2,406,431 31 % Tax (including Deferred Tax) 836,438 637,704 31 % Net Income After Taxes 2,319,933 1,768,727 31 % Net Income After Taxes % to Net Revenues 21 % 23 % EBITDA1 3,201,647 2,204,193 45 % EBITDA1 % to Net Revenues 29 % 29 % EBITDA – is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization. BioSyent Inc. Interim Unaudited Condensed Consolidated Statements of Financial Position AS AT March 31, 2025 December 31, 2024 % Change ASSETS Cash, cash equivalents and short-term investments $ 17,401,557 $ 15,940,971 9 % Trade and other receivables 5,426,657 2,906,829 87 % Inventory 5,277,242 5,328,086 -1 % Prepaid expenses and deposits 484,654 201,971 140 % Derivative asset - 5,790 - Loans receivable - current 52,004 87,433 -41 % CURRENT ASSETS 28,642,114 24,471,080 17 % Long term investments 7,497,025 10,103,571 -26 % Loans receivable - non current 123,170 141,140 -13 % Deferred tax asset 380,206 401,166 -5 % Property and equipment 1,153,985 1,200,992 -4 % Intangible assets 4,965,682 5,041,501 -2 % NON CURRENT ASSETS 14,120,068 16,888,370 -16 % TOTAL ASSETS $ 42,762,182 $ 41,359,450 3 % LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES $ 5,846,653 $ 5,405,106 8 % NON CURRENT LIABILITIES 903,733 951,159 -5 % Long term debt - - 0 % Total Equity 36,011,796 35,003,185 3 % TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 42,762,182 $ 41,359,450 3 % For further information please contact: Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@ 905-206-0013Web: This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
30-04-2025
- Business
- Yahoo
BioSyent to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
MISSISSAUGA, Ontario, April 30, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. ('BioSyent', TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2025 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Monday, May 5th and Tuesday, May 6th, 2025. Mr. René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent's business and corporate activities on Monday, May 5th at 11:30am EDT. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference. These one-on-one meetings can be requested by registered attendees through the conference portal online: About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol 'RX', BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty, and international business units. As of the date of this press release, the Company has 11,254,638 common shares outstanding. For a direct market quote for the TSX Venture Exchange and other Company financial information please visit For further information please contact: Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@ 905-206-0013Web: This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Yahoo
15-03-2025
- Business
- Yahoo
BioSyent Full Year 2024 Earnings: Misses Expectations
Revenue: CA$35.0m (up 11% from FY 2023). Net income: CA$7.27m (up 13% from FY 2023). Profit margin: 21% (in line with FY 2023). EPS: CA$0.63 (up from CA$0.54 in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) also missed analyst estimates by 1.6%. Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Canada. Performance of the Canadian Pharmaceuticals industry. The company's shares are up 2.6% from a week ago. It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with BioSyent (at least 1 which can't be ignored), and understanding them should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
